Ernexa shares jump 11.11% premarket after selection in JETRO's Japan Entry Acceleration Program.

Ernexa Therapeutics (NASDAQ: ERNA) rose 11.11% in premarket trading following its selection as one of only ten global companies to join JETRO’s Japan Entry Acceleration Program (JEAP). The program, part of Japan’s J-Bridge initiative, provides market-entry mentorship, regulatory guidance, and connections with Japanese CDMOs and CROs to accelerate regenerative medicine and oncology development. Ernexa, an oncology-focused participant among six selected in the category, highlighted the program’s role in advancing its pipeline in Japan, including ERNA-101 (first-in-human ovarian cancer trials this year) and ERNA-201 (autoimmune disease). The news underscores the company’s potential to expand its cell therapy platform internationally, leveraging Japan’s leadership in regenerative medicine and its progressive regulatory framework.